Faeth Therapeutics, Inc. approved one-time supplemental performance-based stock option grants to CEO Anand Parikh (398,018 shares), General Counsel Christopher Gerry (84,766 shares), and SVP Finance Josiah Craver (30,824 shares) under the 2026 Equity Incentive Plan. The options vest upon achieving a $70.00 stock price hurdle within a four-year performance period. Faeth Therapeutics, Inc. is a biotechnology company focused on metabolic diseases.

Faeth Therapeutics, Inc. entered into a Sales Agreement with TD Securities (USA) LLC to establish an at-the-market (ATM) offering of up to $150,000,000 in common stock. Additionally, 24,435,594 shares of Series B Non-Voting Convertible Preferred Stock automatically converted into common stock on June 15, 2026, bringing the total outstanding common stock to 25,778,754 shares. Faeth Therapeutics, Inc. is a biotechnology company focused on metabolic diseases.

Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics, Inc.) announced a name change and a new trading symbol, FTH, effective June 15, 2026. The company also announced several leadership changes, including the appointment of Anand Parikh as President and CEO, Brian Stephenson as CFO, and Josiah Craver as Senior VP of Finance. Additionally, the company terminated a $50 million sales agreement with Jefferies LLC. Faeth Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cancer and other diseases.

On June 10, 2026, stockholders approved an amendment to the Certificate of Incorporation increasing authorized common stock from 12.5 million to 300 million shares. Stockholders also approved the issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock, which will result in a change of control and exceed 20% of outstanding shares. Additionally, the company adopted a 2026 Equity Incentive Plan with an initial reserve of 2,671,981 shares (plus up to 311,164 shares from the 2021 plan) and a 2026 Employee Stock Purchase Plan with an initial reserve of 267,198 shares. Both plans include automatic annual increases through 2036. Sensei Biotherapeutics, Inc. is a biotechnology company that develops therapeutic treatments.